Literature DB >> 24361417

Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics.

Cynthia Levy1, Jahnavi Naik2, Christin Giordano3, Amar Mandalia4, Christopher O'Brien3, Kalyan R Bhamidimarri3, Eugene R Schiff3, Paul Martin3.   

Abstract

BACKGROUND & AIMS: Primary biliary cirrhosis (PBC) is a cholestatic disease that predominantly affects middle-aged Caucasian women. Studies have suggested that PBC has a more aggressive course in individuals of Hispanic ancestry. We investigated the clinical presentation and progression of PBC in an ethnically diverse population.
METHODS: We performed a cross-sectional study, analyzing data from Hispanic (n = 70) and non-Hispanic patients (n = 134) with PBC seen at the University of Miami/Jackson Memorial Hospital from January 1, 2000, through December 31, 2011. We compared demographics, clinical presentation, response to therapy, and outcomes between the groups.
RESULTS: Age at diagnosis, antimitochondrial antibody positivity, frequency of advanced histologic stage, use and dose of ursodeoxycholic acid (UDCA), and the presence of pruritus or fatigue were similar between groups. Hypothyroidism was less frequent among Hispanics (16% vs 29% in non-Hispanics; P = .04). Hispanic subjects were more likely to have overlap syndrome of PBC and autoimmune hepatitis than non-Hispanics (31% vs 13%; P = .002). After a median follow-up period of 3.65 years, a greater percentage of Hispanics had ascites (24% vs 12%; P = .03) and variceal bleeding (20% vs 7%; P = .01), although there were no differences in the number of deaths or liver transplants. Of 204 total patients, 180 received UDCA for at least 1 year. A lower proportion of Hispanic patients had a biochemical response to treatment (60% vs 88%; P < .0001). Independent predictors of poor biochemical response were younger age at diagnosis and Hispanic ethnicity.
CONCLUSIONS: In a cross-sectional study, patients of Hispanic ethnicity with PBC had an increased prevalence of overlap syndrome, reduced response to UDCA treatment, and more frequent complications of portal hypertension than non-Hispanic patients.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholestasis; Ethnic Origin; Health Disparities; Prognosis

Mesh:

Substances:

Year:  2013        PMID: 24361417     DOI: 10.1016/j.cgh.2013.12.010

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  10 in total

1.  Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.

Authors:  George Cholankeril; Humberto C Gonzalez; Sanjaya K Satapathy; Stevan A Gonzalez; Menghan Hu; Mohammad Ali Khan; Eric R Yoo; Andrew A Li; Donghee Kim; Satheesh Nair; Robert J Wong; Paul Y Kwo; Stephen A Harrison; Zobair M Younossi; Keith D Lindor; Aijaz Ahmed
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-08       Impact factor: 11.382

2.  Race/Ethnicity and Insurance-Specific Disparities in In-Hospital Mortality Among Adults with Primary Biliary Cholangitis: Analysis of 2007-2014 National Inpatient Sample.

Authors:  Artin Galoosian; Courtney Hanlon; Michele Tana; Ramsey Cheung; Robert J Wong
Journal:  Dig Dis Sci       Date:  2019-09-05       Impact factor: 3.199

Review 3.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

4.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

Review 5.  Female gender in the setting of liver transplantation.

Authors:  Kryssia Isabel Rodríguez-Castro; Eleonora De Martin; Martina Gambato; Silvia Lazzaro; Erica Villa; Patrizia Burra
Journal:  World J Transplant       Date:  2014-12-24

Review 6.  Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; George K Koukoulis; George N Dalekos
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

7.  Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved.

Authors:  Briton Lee; Edward W Holt; Robert J Wong; Justin L Sewell; Ma Somsouk; Mandana Khalili; Jacquelyn J Maher; Michele M Tana
Journal:  Autoimmunity       Date:  2018-06-11       Impact factor: 2.815

Review 8.  Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Authors:  Treta Purohit; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2015-05-08

9.  Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona.

Authors:  Susanna Tan; Napatkamon Ayutyanont; Bikash Bhattarai; Zohreh Movahedi; Lakshmi Jayaram; Robert Gish; Abdul Nadir
Journal:  BMJ Open Gastroenterol       Date:  2017-09-25

Review 10.  Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Benjamin L Freedman; Christopher J Danford; Vilas Patwardhan; Alan Bonder
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.